For some time now, we have been writing, discussing, and suggesting that there is great value in thinking about genetic and other “omic” data when defending toxic tort or product liability cases involving disease allegations of any kind. But these “omic” data are especially critical in cases involving allegations of cancer causation.
On this note, we were intrigued when we saw a recent post reporting that defense experts and lawyers in asbestos litigation spent some time thinking about the Human Papilloma Virus (HPV) as a …
Continue Reading